Loading...

Kelly Kersten, PhD

Title(s)Postdoctoral Scholar, Pathology
SchoolSchool of Medicine
Address513 Parnassus Ave, HSW
San Francisco CA 94143
Phone415-514-3251
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Netherlands Cancer Institute, Amsterdam, The NetherlandsPh.D.02/2017Tumor-induced inflammation
    Utrecht University, Utrecht, The NetherlandsM.S.02/2011Cancer Genomics & Developmental Biology
    Utrecht University, Utrecht, The NetherlandsB.S.09/2008Biology

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system. Oncoimmunology. 2020; 9(1):1724049. Klarenbeek S, Doornebal CW, Kas SM, Bonzanni N, Bhin J, Braumuller TM, van der Heijden I, Opdam M, Schouten PC, Kersten K, de Bruijn R, Zingg D, Yemelyanenko J, Wessels LFA, de Visser KE, Jonkers J. PMID: 32117586.
      View in: PubMed   Mentions:
    2. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell. 2019 04 18; 177(3):556-571.e16. Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, Spasic M, Giurintano JP, Chan V, Daud AI, Ha P, Ye CJ, Roberts EW, Krummel MF. PMID: 30955881.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    3. Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nat Cell Biol. 2019 04; 21(4):511-521. Salvagno C, Ciampricotti M, Tuit S, Hau CS, van Weverwijk A, Coffelt SB, Kersten K, Vrijland K, Kos K, Ulas T, Song JY, Ooi CH, Rüttinger D, Cassier PA, Jonkers J, Schultze JL, Ries CH, de Visser KE. PMID: 30886344.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    4. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Oncoimmunology. 2018; 7(12):e1509820. Sobral-Leite M, Van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM, Severson TM, Mulligan AM, Weerasooriya N, Sanders J, Glas AM, Wehkamp D, Mittempergher L, Kersten K, Cimino-Mathews A, Peters D, Hooijberg E, Broeks A, van de Vijver MJ, Bernards R, Andrulis IL, Kok M, de Visser KE, Schmidt MK. PMID: 30524905.
      View in: PubMed   Mentions:
    5. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018 05; 24(5):541-550. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF. PMID: 29686425.
      View in: PubMed   Mentions: 102     Fields:    Translation:Humans
    6. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1ß in tumor-associated macrophages. Oncoimmunology. 2017; 6(8):e1334744. Kersten K, Coffelt SB, Hoogstraat M, Verstegen NJM, Vrijland K, Ciampricotti M, Doornebal CW, Hau CS, Wellenstein MD, Salvagno C, Doshi P, Lips EH, Wessels LFA, de Visser KE. PMID: 28919995.
      View in: PubMed   Mentions:
    7. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med. 2017 02; 9(2):137-153. Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. PMID: 28028012.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimals
    8. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol. 2015; 6:516. Kersten K, Salvagno C, de Visser KE. PMID: 26500653.
      View in: PubMed   Mentions: 10     Fields:    
    9. Adaptive Immune Regulation of Mammary Postnatal Organogenesis. Dev Cell. 2015 Sep 14; 34(5):493-504. Plaks V, Boldajipour B, Linnemann JR, Nguyen NH, Kersten K, Wolf Y, Casbon AJ, Kong N, van den Bijgaart RJ, Sheppard D, Melton AC, Krummel MF, Werb Z. PMID: 26321127.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    10. IL-17-producing ?d T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015 Jun 18; 522(7556):345-348. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, de Visser KE. PMID: 25822788.
      View in: PubMed   Mentions: 240     Fields:    Translation:AnimalsCells
    Kelly's Networks
    Concepts (56)
    Derived automatically from this person's publications.
    _
    Co-Authors (11)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _